)
Visual21 Nov 2025
Data center suppliers
Curis (CRIS) investor relations material
Curis Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Progress in clinical studies for emavusertib in PCNSL, CLL, and AML, with ongoing enrollment and new data presentations scheduled at major oncology conferences.
Emavusertib granted orphan drug designation by FDA and EMA for PCNSL; protocol for Phase 2 CLL study filed, with first patient dosing expected late Q4 2025 or early Q1 2026.
Recently sold royalty interest in Erivedge and related assets for $2.5 million, extinguishing a significant liability and ending future royalty revenue.
Accumulated deficit reached $1.3 billion as of September 30, 2025, with continued operating losses and substantial doubt about the ability to continue as a going concern.
Completed registered direct offering and private placement, extending cash runway into 2026.
Financial highlights
Net loss for Q3 2025 was $7.7 million ($0.49/share), improved from $10.1 million ($1.70/share) in Q3 2024; net loss for the nine months ended September 30, 2025, was $26.9 million ($2.19/share), down from $33.8 million ($5.77/share) in 2024.
Revenues for Q3 2025 were $3.2 million, up from $2.9 million in Q3 2024, primarily from Erivedge royalties.
R&D expenses for Q3 2025 were $6.4 million, down from $9.7 million in Q3 2024; G&A expenses were $3.7 million, slightly down from $3.8 million.
Cash and cash equivalents stood at $9.1 million as of September 30, 2025, with 12.7 million shares outstanding.
Weighted average shares outstanding increased to 15.7 million in Q3 2025 from 5.9 million in Q3 2024.
Outlook and guidance
Existing cash and equivalents expected to fund operations into Q1 2026; additional capital required to fund operations beyond that period.
Focused on enrolling additional patients for TakeAim Lymphoma to support regulatory submissions.
First patient in CLL Phase 2 study expected to be dosed late Q4 2025 or early Q1 2026, with data anticipated at ASH 2026.
Plans to seek additional funding through equity, collaborations, or strategic transactions, but faces significant difficulty raising capital.
If unable to secure funding, may need to delay or eliminate R&D programs, consider asset sales, or seek bankruptcy protection.
What are the immediate funding plans?
How do AML triplet DLTs impact future dosing?
CLL study: What defines time-limited treatment?
CLL study: What CR rate would be a strong signal?
Strategy for year-end capital raise
When are PCNSL accelerated submissions expected?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Curis earnings date
Q4 202526 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Curis Inc. is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company's research and development efforts concentrate on targeting signaling pathways that play a key role in the growth and survival of cancer cells. Curis works on both proprietary drug candidates and in collaboration with strategic partners to advance its oncology-focused pipeline. Its therapeutic approach includes small molecules and immunotherapies aimed at addressing various forms of cancer, with the goal of improving patient outcomes. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage